Holen Sie sich die Stockscreener-App
9.80
1.61%
-0.16
Vorhandelsmarkt:
9.80
Evolus Inc Aktie (EOLS) Neueste Nachrichten
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EO - GuruFocus
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Midday Stock Roundup: Activist Investor Targets El Pollo Loco - Orange County Business Journal
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - marketscreener.com
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus CFO Sandra Beaver resigns for new role - Investing.com
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to 16 newly hired non-executive employees - BioSpace
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Evolus Executives Sell Shares to Cover Tax Obligations - TradingView
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Voya Investment Management LLC - Defense World
Evolus, Inc. (EOLS): A Bull Case Theory - Insider Monkey
Evolus (NASDAQ:EOLS) Earns Buy Rating from Needham & Company LLC - Defense World
Evolus projects $345M-$355M revenue for 2025 with new product launches - MSN
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report - simplywall.st
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Arcus Biosciences (RCUS) - The Globe and Mail
Evolus, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
EOLS Stock: Needham Reiterates Buy Rating with $22 Target | EOLS Stock News - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Evolus Stock - Benzinga
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Yahoo Finance
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges By GuruFocus - Investing.com Canada
1.38%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):